

## First authorships

- Al-Mashhadi, Z. K.**, Viggers, R., Fuglsang-Nielsen, R., Vestergaard, P., Gregersen, S., & Starup-Linde, J. (2022). *The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A danish nationwide cohort study*. *Frontiers in Endocrinology*, 13. <https://doi.org/10.3389/fendo.2022.882998>
- Al-Mashhadi, Z. K.**, Viggers, R., Starup-Linde, J., Vestergaard, P., & Gregersen, S. (2022). *SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study*. *Frontiers in Endocrinology*, 13. <https://doi.org/10.3389/fendo.2022.861422>
- Al-Mashhadi, Z.**, Viggers, R., Fuglsang-Nielsen, R., Langdahl, B., Vestergaard, P., Gregersen, S., & Starup-Linde, J. (2020). *Bone health in the elderly with type 2 diabetes mellitus—a systematic review*. *OBM Geriatrics*, 4(2), 1–65. <https://doi.org/10.21926/obm.geriater.2002123>
- Al-Mashhadi, Z.**, Viggers, R., Fuglsang-Nielsen, R., Vries, F. de, Bergh, J. P. van den, Harsløf, T., Langdahl, B., Gregersen, S., & Starup-Linde, J. (2020). *Glucose-lowering drugs and fracture risk—a systematic review*. *Current Osteoporosis Reports*, 18(6), 737–758. <https://doi.org/10.1007/s11914-020-00638-8>

## Co-authorships

- Mellbye, F. D., Nguyen, M. D., Hermansen, K., Jeppesen, P. B., **Al-Mashhadi, Z. K.**, Ringgaard, S., & Gregersen, S. (2024). *Effects of 12-week supplementation with coffee diterpene cafestol in healthy subjects with increased waist circumference: A randomized, placebo-controlled trial*. *Nutrients*, 16(19), 3232. <https://doi.org/10.3390/nu16193232>
- Starup-Linde, J., Westberg-Rasmussen, S., Viggers, R., **Al-Mashhadi, Z. K.**, Handberg, A., Vestergaard, P., & Gregersen, S. (2024). *Serum osteoglycin is stable during various glycemic challenges in healthy men*. *Endocrine*, 85(3), 1117–1121. <https://doi.org/10.1007/s12020-024-03789-1>
- Hulten, V. van, Driessen, J. H. M., Starup-Linde, J. K., **Al-Mashhadi, Z. K.**, Viggers, R., Klungel, O. H., Souverein, P. C., Vestergaard, P., Stehouwer, C. D. A., & Bergh, J. P. van den. (2023). *The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus*. *Diabetes, Obesity and Metabolism*, 25(11), 3235–3247. <https://doi.org/10.1111/dom.15220>
- Viggers, R., **Al-Mashhadi, Z.**, Starup-Linde, J., & Vestergaard, P. (2022). *The efficacy of alendronate versus denosumab on major osteoporotic fracture risk in elderly patients with diabetes mellitus: A danish retrospective cohort study*. *Frontiers in Endocrinology*, 12. <https://doi.org/10.3389/fendo.2021.826997>
- Al-Mashhadi, R. H., Al-Mashhadi, A. L., Nasr, Z. P., Mortensen, M. B., Lewis, E. A., Camafeita, E., Ravlo, K., **Al-Mashhadi, Z.**, Kjær, D. W., Palmfeldt, J., Bie, P., Jensen,

- J. M., Nørgaard, B. L., Falk, E., Vázquez, J., & Bentzon, J. F. (2021). *Local pressure drives low-density lipoprotein accumulation and coronary atherosclerosis in hypertensive minipigs*. *Journal of the American College of Cardiology*, 77(5), 575–589. <https://doi.org/10.1016/j.jacc.2020.11.059>
- Viggers, R., **Al-Mashhadi, Z.**, Starup-Linde, J., & Vestergaard, P. (2021). *Alendronate use and risk of type 2 diabetes: A nationwide danish nested case-control study*. *Frontiers in Endocrinology*, 12. <https://doi.org/10.3389/fendo.2021.771426>
- Viggers, R., **Al-Mashhadi, Z.**, Fuglsang-Nielsen, R., Gregersen, S., & Starup-Linde, J. (2020). *The impact of exercise on bone health in type 2 diabetes mellitus—a systematic review*. *Current Osteoporosis Reports*, 18(4), 357–370. <https://doi.org/10.1007/s11914-020-00597-0>
- Al-Mashhadi, R. H., Tolbod, L. P., Bloch, L. Ø., Bjørklund, M. M., Nasr, Z. P., **Al-Mashhadi, Z.**, Winterdahl, M., Frøkiær, J., Falk, E., & Bentzon, J. F. (2019). *<sup>18</sup>Fluorodeoxyglucose accumulation in arterial tissues determined by PET signal analysis*. *Journal of the American College of Cardiology*, 74(9), 1220–1232. <https://doi.org/10.1016/j.jacc.2019.06.057>

## Conference abstracts

- Al-Mashhadi, Z. K.**, Viggers, R., Fuglsang-Nielsen, R., Vestergaard, P., Gregersen, S., & Starup-Linde, J. (2022). *Fracture risk in treatment with GLP-1RA compared to DPP-4i: A Danish nationwide cohort study*. *Diabetologia*, 65, suppl. 1, Abstract no. 351, S183.
- Al-Mashhadi, Z. K.**, Viggers, R., Starup-Linde, J., Vestergaard, P., & Gregersen, S. (2022). *SGLT2 inhibitor treatment does not increase risk of osteoporotic fractures compared to GLP-1 receptor agonists: A danish population-based cohort study*. *Endocrine Abstracts*. <https://doi.org/10.1530/endoabs.81.oc8.2>

## Works in progress

- Al-Mashhadi, Z. K.**, Viggers, R., Starup-Linde, J., Langdahl, B. L., van Hulten, V., van den Bergh, J. P., Driessen, J., Vestergaard, P., & Gregersen, S. (n.d.). Systemic glucocorticoid use increases fracture risk equally in those with and without type 2 diabetes mellitus: A Danish nationwide cohort study [Work in Progress].